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9 ABSTRACT: HIV-1 protease is a key enzyme in the life cycle of HIV/AIDS, as it
10 is responsible for the formation of the mature virus particle. We demonstrate here
11 that phage-display peptides raised against this enzyme can be used as peptide
12 sensors for the detection of HIV-1 protease in a simple, one-pot assay. The
13 presence of the enzyme is detected through an energy transfer between two
14 peptide sensors when simultaneously complexed with the target protein. The
15 multivalent nature of this assay increases the speciﬁcity of the detection by
16 requiring all molecules to be interacting in order for there to be a FRET signal.
17 We also perform molecular dynamics simulations to explore the interaction
18 between the protease and the peptides in order to guide the design of these
19 peptide sensors and to understand the mechanisms which cause these
20 simultaneous binding events. This approach aims to facilitate the development
21 of new assays for enzymes that are not dependent on the cleavage of a substrate
22 and do not require multiple washing steps.
23 ■ INTRODUCTION
24 Human immunodeﬁciency virus type 1 (HIV-1) is the most
25 common cause of acquired immune deﬁciency syndrome
26 (AIDS) worldwide, with some 2.1 million new cases being
27 diagnosed in 2013.1 HIV-1 protease (HIV-1 PR) is a dimeric
28 enzyme from the family of aspartic proteases. It is a crucial
29 enzyme in the lifecycle of the HIV virion, being responsible for
30 the cleavage of the precursor polyproteins into the mature virus
31 particle.2 The virus remains ineﬀective without the presence of
32 an active form of this enzyme, leading it to be considered as the
33 major clinical target for antiretroviral therapies.3 Although it has
34 been widely exploited as a drug target and exhibits broad
35 substrate recognition, only a few studies document the use of
36 the enzyme as a biomarker for HIV infection.4−7 While these
37 methods report detection limits in the low picomolar range
38 (LOD < 1 pM), they are limited in their eﬀectiveness as point-
39 of-care diagnostics given their reliance on detection mecha-
40 nisms involving complex instrumentation such as surface
41 plasmon resonance (SPR) or quartz crystal microbalance
42 (QCM). Furthermore, in these approaches the signal is
43 generated by the cleavage of a peptide substrate by the HIV-
44 1 PR, and therefore, they are also susceptible to false positives,
45 since the peptides could be cleaved nonspeciﬁcally by other
46 proteases.
47 Traditional HIV diagnostics are divided into three main
48 categories: those which detect the patient’s antibodies against
49 HIV, those which detect the p24 antigen, and those which rely
50 on RT-PCR for the detection of viral load DNA.8 While these
51techniques are highly sensitive, they too suﬀer from the
52requirements of expensive equipment and reagents as well as
53highly skilled, laboratory-trained staﬀ, making it unsuitable for
54use in resource-limited settings. A full discussion of HIV
55diagnostic tools is beyond the scope of this Article, but
56comprehensive reviews can be found by Suaifan et al.9 and
57Cornett and Kirn.10
58Förster resonance energy transfer (FRET) has long been
59used as a tool to study active enzymes, in particular, proteases.11
60We have previously reported the use of FRET to detect the
61presence of disease related enzymes in serum.12,13 In these
62studies the single event that is monitored is the cleavage of a
63peptide tagged with a pair of ﬂuorescent FRET probes. The
64peptide acts as the substrate for the enzyme of interest so that
65in the presence of the enzyme the peptide is cleaved and the
66FRET disappears. FRET is well-suited for this detection as
67energy transfer will only occur between two nonradiatively
68coupled ﬂuorophores if they are within 10 nm of each other,
69allowing detection from a single recognition event to occur.
70However, this same advantage can limit the complexity of
71systems that can be studied since the detection probe must be
72carefully designed to enable an eﬃcient signal. Due to the
73strong distance dependence on energy transfer eﬃciency (r6), it
74can be challenging to design an enzyme substrate that is short
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75 enough to fall within this range but long enough to be resistant
76 to nonspeciﬁc cleavage.
77 Herein we describe a FRET-based method of detection of
78 HIV-1 protease using multiple recognition elements which does
f1 79 not rely on peptide cleavage (Figure 1). These peptide sensors
80 are designed to interact independently but in close proximity of
81 each other, allowing the generation of a strong FRET signal.
82 The use of multiple biorecognition events also increases the
83 speciﬁcity of the assay since FRET will only occur when
84 multiple sensors are bound to the same HIV-1 PR molecule.
85 Our sensors rely on peptide biorecognition elements: short
86 peptide sequences that recognize HIV-1 PR. These peptide
87 sequences are then labeled with ﬂuorescent dye molecules to
88 actuate the detection signal. The position of the interaction
89 between the ﬁrst peptide sensor and the protease is determined
90 by choosing a known inhibitory peptide sequence of the
91 enzyme (LLEYSL, identiﬁed by Lee and Maruyama).14 Being a
92 competitive inhibitor peptide, it must interact in the active site
93 of the enzyme. A selection of complementary recognition
94 peptides that interact with other regions of the protein was
95 identiﬁed through phage display. Phage display is a powerful
96 technique to identify peptide sequences which show an aﬃnity
97 for a particular target. While it has been most successful in
98 identifying sequences which bind inorganic surfaces,15 it has
99 also been heavily utilized to identify sequences that can have
100 applications in drug discovery16 and toward the design of
101 synthetic antibody libraries.17 Phage-display derived peptides
102 have also successfully been used as biorecognition elements in
103 biosensors.18
104 While peptides have an intrinsically lower binding aﬃnity
105 than larger protein molecules such as antibodies15 on account
106 of their lack of secondary structure, they remain well-suited to
107 their use as protein recognition elements due to their simple
108 chemical structure and ease of synthesis compared to large
109 proteins. They can also be easily incorporated into more
110 complex nanomaterials19 as they are more stable to harsh
111 environments such as low pH or temperature which can alter
112 the conformation of protein-based materials. This makes them
113 ideal for use in sensing applications, especially with regard to
114 point-of-care diagnostic tools in resource-limited settings.
115 ■ MATERIALS AND METHODS
116 Experimental Methods. Enzymes. Recombinant HIV-1 protease
117 was purchased from BioVendor and used as received. Lyophilized, salt-
118 free pepsin (Sigma-Aldrich) at >2500 units/mg was resuspended in
119 the appropriate assay buﬀer at 4 mg/mL. Lyophilized Papain
120(Worthington Biochemicals) was prepared to 20 units/mL in the
121appropriate assay buﬀer.
122Phage Display. A Ph.D.-7 phage display kit (New England Biolabs)
123was purchased, and the recommended protocol20 was followed. In
124brief, 2.4 μM HIV-1 protease was coated onto the surface of a well of
125Nunc-Immuno MicroWell 96 well plate in 0.1 M NaHCO3 and left at
1264 °C overnight. The well was then washed and blocked with a blocking
127buﬀer of 5 mg/mL bovine serum albumin (BSA) in TBS for an hour.
128After washing to remove bound proteins, 5 μL of the phage library was
129added to each well in 95 μL Tris buﬀered saline with 0.05% (v/v)
130Tween-20, pH 7.4 (TBST). The phage was allowed to interact for an
131hour before nonbound phage was removed through vigorous washing.
132Bound phage was eluted with 0.2 M glycine-HCl (pH 2.2) including 1
133mg/mL BSA. The eluted phage was then neutralized with the addition
134of 1 M Tris-HCl (pH 9.1) and then added to 20 mL of E. coli ER2738
135and left to grow for 5 h for ampliﬁcation. The eluted phage was
136quantiﬁed by plating these E. coli on LB XGal/IPTG plates. Since the
137library phages are derived from the M13mp19 vector, which carries the
138lacZa gene, phage-infected plaques acquired a blue color when plated
139on media containing Xgal (5-bromo-4-chloro-3-indoyl-b-D-galacto-
140side) and IPTG (isopropyl-b-D-thiogalactoside). Colored plaques were
141picked, and DNA was sequenced from these plates (sequencing was
142carried out by GATC Biotech, Germany). Subsequent biopanning
143rounds were then carried out by applying the eluted and ampliﬁed
144phage to plated HIV-1 protease. Three rounds of biopanning were
145carried out in this manner.
146Peptides. Sensor peptides were synthesized by standard automated
147Fmoc solid-phase peptide synthesis as described earlier. Synthesis used
148a Rink-amide solid resin on a PTI Quartet peptide synthesizer. The
149peptides were cleaved and deprotected with 95:2.5:2.5 triﬂuoroacetic
150acid (TFA)/triisopropylsilane/H2O for 3 h and precipitated and
151washed with cold diethyl ether. The crude peptides were puriﬁed to
152>95% (determined by LC−MS) on a preparative C18 HPLC column
153using a water/acetonitrile mobile phase containing 1% (v/v) TFA.
154Biotinylated peptides were purchased at >95% purity from Genscript.
155ELISA. Nunc-Immuno MicroWell 96-well solid plates were coated
156with 1.2 μM HIV-1 protease in 0.1 M NaHCO3 and incubated
157overnight at 4 °C. BSA was prepared at 1 mg/mL and coated in the
158same buﬀer as a control. Wells were then blocked with 2% (w/v) skim
159milk for 1 h at room temperature and washed well with PBST (0.05%
160(v/v) Tween-20). Biotinylated peptides, dissolved in PBS with 10%
161(v/v) DMSO, were then added at 100 μg/mL to each well and left to
162incubate for 1 h at room temperature. The plate was then washed
163again in PBST before the addition of streptavidin-linked hydrogen
164peroxidase and left to incubate for 45 min. The presence of the peptide
165was quantiﬁed by the addition of a tetramethylbenzidine (TMB)
166colorimetric substrate, and the absorbance at 450 nm was measured.
167Inhibition Assay. An assay to measure the inhibition of HIV-1
168protease was performed using a ﬂuorogenic substrate of HIV-1
169protease,21 purchased from Sigma-Aldrich. This is a synthetic peptide
170sequence that contains the HIV-1 PR cleavage site (Tyr-Pro) and two
171covalently modiﬁed amino acids labeled with a FRET pair (EDANS, 5-
1722(aminoethylamino)-1-napthalenesulfonate and DABCYL, 4,4-dime-
173thylaminoazobenzene-4-carboxylate). The substrate was prepared in a
174500 μM stock solution in dimethyl sulfoxide (DMSO). Assays were
175performed at room temperature in a buﬀered solution of 0.1 M sodium
176acetate, 1.0 M sodium chloride, 1.0 mM ethylenediaminetetraacetic
177acid (EDTA), 1.0 mM dithiothreitol (DTT), 10% (v/v) DMSO, and 1
178mg/mL BSA at pH 4.7. Enzyme and substrate concentrations were
179kept constant at 240 nM and 10 μM, respectively. Measurements of
180the intensity at 490 nm were taken over 3 min in a FluoroLog
181spectrophotometer (Horiba).
182Fluorophore-Peptide Labeling. Alexa Fluor 647 was purchased as a
183succinimidyl ester from Life Technologies. The dyes were dissolved to
1841 mg/mL in dimethyl sulfoxide and coupled at a 1:1 ratio with puriﬁed
185peptides including 1 equiv of 1-ethyl-3-(3-(dimethylamino)propyl)
186carbodiimide (EDC) and 0.2 equiv of 4-dimethylaminopyridine
187(DMAP). The reaction was left overnight at room temperature. The
188solution was then diluted 10× into an acidic mobile phase of water/
189acetonitrile containing 0.1% (v/v) TFA and puriﬁed on a semi-
Figure 1. Schematic of the detection mechanism of HIV-1 protease.
(1) A ﬂuorescent nanosensor binds speciﬁcally to the HIV-1 PR
molecule (peptide nanosensor 1 WSRVGYW-AF647). (2) A second
nanosensor (peptide nanosensor 2 LLEYSL-BHQ-3), tagged with a
ﬂuorescent quencher, interacts with the active site of the protease. The
biorecognition events trigger an energy transfer process between
peptide nanosensors 1 and 2, and the signal from the ﬂuorescent dye
decreases.
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190 preparative HPLC using a C18 column. Colored fractions were
191 collected and analyzed by UV−vis spectroscopy to identify the single
192 fraction containing peaks at 220 and 280 nm (indicative of the peptide
193 backbone) and 647 nm (corresponding to the Alexa Fluor dye).
194 Peptides conjugated to these dyes were not seen through LC-MS or
195 MALDI as has been reported previously,22 and a full discussion can be
196 found in the Supporting Information (Figure S9). BHQ-3 as a
197 succinimidyl ester was purchased from Biosearch Technologies and
198 conjugated in the manner described above. Fractions collected after
199 HPLC puriﬁcation were identiﬁed via LC−MS showing an MW of
200 1443.7 (expected 1410.59, observed mass in positive mode = M +
201 methanol + H+).
202 NHS-ﬂuorescein and NHS-rhodamine were purchased from Pierce
203 Biotechnology. The dyes were dissolved in DMSO to 100 mM. The
204 dyes were then added at a 1:1 ratio to the protected peptides on resin.
205 The dyes were allowed to couple overnight at room temperature in
206 dimethylformamide (DMF) with 25 μL of N,N-diisopropylethylamine
207 (DIPEA). The peptides were then cleaved from the resin and puriﬁed
208 as described above. Fractions collected after HPLC were identiﬁed via
209 LC−MS showing an MW of 1093.5 (LLE-ﬂuor, expected: 1094.27,
210 observed mass in negative mode = M − H+) and 683 (WSR-rhod,
211 expected: 1364.6, observed mass in positive mode = M + 2H+).
212 FRET Surface Assay. Amine functionalized glass slides (Sigma-
213 Aldrich) were immersed in 0.1 M sodium bicarbonate (pH 8.6) with
214 10% (v/v) glutaraldehyde and left for 1 h. The slides were then
215 washed thoroughly with deionized water before being dried with
216 nitrogen. HIV-1 protease was prepared at 50 μg/mL in 0.1 M sodium
217 bicarbonate with 10 mM sodium cyanoborohydride. A 10 μL portion
218 of the protein solution was spotted onto the preprepared glass slide
219 and left for 3 h in a humidity chamber. The slides were then washed
220 thoroughly with deionized water. Unreacted amines were blocked with
221 a solution of 1 M ethanolamine in 0.1 M sodium bicarbonate with 1%
222 (w/v) BSA (at pH 8.6). The slides were left to block for 1 h and then
223 washed thoroughly. The slide was immersed in WSR-647 for 1 h in the
224dark before being washed in PBST (0.05% (v/v) Tween-20), before
225being imaged at 700 nm with a Li-Cor Odyssey infrared scanner. Half
226the slide was then immersed in LLE-BHQ-3 while the other half was
227left in PBST for an hour in the dark. The slide was then washed
228thoroughly with PBST again and reimaged. The intensity of the spots
229was quantiﬁed using Li-Cor Image Studio.
230In Solution FRET. LLE-ﬂuor and WSR-rhod at 20 μM were added
231to varying concentrations of HIV-1 PR in the PR assay buﬀer
232described above, adjusted to pH 6 to a ﬁnal volume of 60 μL in the
233wells of a 384 clear-bottom black microwell plate. The plate was
234incubated in the dark at 4 °C for an hour before the ﬂuorescent spectra
235were read on a SpectraMax M5 plate reader (Molecular Devices). The
236solution was excited at 480 nm, and the emission was read between
237510 and 600 nm with a cutoﬀ value of 495 nm.
238Computational Methods. Structure Preparation. For the HIV-1
239protease, crystal structures with the protease ﬂaps open (PDB ID
2402PC0), semiopen (PDB ID 1HHP), and closed (PDB ID 1HVC)
241were used. Two side chains were changed (I3V and C95A) in 1HHP
242to match the native protease sequence. For 1HVC, the structural,
243active-site water molecule, HOH-415, was retained for docking, but all
244other crystallographic water was removed. Hydrogens were added to
245the structures using AutoDockTools (ADT) from Autodock 4.2.23
246Docking. Initial conﬁgurations for the peptide−protease complexes
247were generated using the docking program Autodock 4.2, with default
248settings used unless otherwise noted. Three overlapping grids were
249deﬁned on the basis of areas of interest (Supporting Information,
250Figure S6). WSRVGYW and LLEYSL were used as ligands, with
251Gasteiger charges assigned by ADT. Each peptide was docked into
252each grid for the three protease structures, with a maximum of
25310 000 000 energy evaluations and 27 000 genetic algorithm
254generations using the Lamarckian Genetic Algorithm. For each
255docking run, the top 100 structures based on the Autodock estimation
256of free energy of binding were examined, and the 3D structures of the
257top 10 were evaluated for geometric ﬁt variation to select the
Figure 2. Characterization of ﬁve peptide sequences isolated from phage display as potential binders to HIV-1 protease. (a) ELISA showing binding
of sequences to HIV-1 protease compared to BSA as a control protein. Error bars shown are standard deviation (n = 3). Signiﬁcance is given by a
two-tailed student t test. * = p < 0.05, ** = p < 0.01, *** = p < 0.005. (b) Competitive inhibition assay of sequences in the presence of a large excess
of phage-display peptides (10 μM). The peptide WSRVGYW partially inhibits the enzyme at high concentrations. (c) Amino acid structures of
selected peptides.
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258 distinctive starting structures for subsequent molecular dynamics
259 (MD) simulations.
260 Molecular Dynamics. MD simulations were performed using the
261 Amber 12 MD code24 and Amber force ﬁeld.25 The systems were
262 solvated with a TIP3P water26 box extending at least 12 Å from the
263 complex resulting in a box containing approximately 34 000−36 000
264 atoms. Chloride ions were added to neutralize the overall charge.
265 Asp25 in the catalytic site was protonated to mimic the PR in its native
266 conﬁguration.27 Bond lengths involving hydrogen were constrained
267 using the SHAKE algorithm.28 The particle-mesh Ewald scheme was
268 used for the electrostatic interactions, with a nonbond interaction
269 cutoﬀ (electrostatics and van der Waals) of 8 Å.
270 Prior to dynamics, the systems were minimized using the steepest
271 descent algorithm, followed by a conjugate gradient method, with a
272 convergence criterion of 10−4 kcal/mol Å. Position restraints of 2 kcal/
273 mol Å2 were maintained on the protein and peptide atoms during
274 minimization and equilibration. Equilibration consisted of 50 ps of
275 constant-volume MD as the system was heated from 0 to 300 K,
276 followed by 50 ps of constant pressure MD. Unrestrained simulations
277 of up to 20 ns were performed for each system, with atomic
278 coordinates saved every 10 ps. A 2 fs time step was used. Temperature
279 was maintained at 300 K by a Langevin thermostat, and pressure was
280 maintained at 1 atm by a Berendsen barostat.
281 ■ RESULTS AND DISCUSSION
282 To identify peptide sensor 1, phage display was carried out
283 against immobilized HIV-1 PR. A Ph.D.-7 phage-display library
284 from New England Biolabs containing approximately 1011
285 clones of 109 individual sequences was incubated against the
286 target protein. Three rounds of biopanning were carried out,
287 and enrichment was observed (Supporting Information, Figure
288 S1). Some 32 clones were then selected for sequencing and
289 were then assessed for binding to HIV-1 PR. Binding was
290 established through an enzyme-linked immunosorbent assay
291 (ELISA) against the M13 bacteriophage, and from this, ﬁve
292 candidates were selected and sequenced. These were then
f2 293 synthesized and further characterized (Figure 2). Through an
294 ELISA-like enzyme linked binding assay utilizing biotinylated
295 peptides, all ﬁve candidates showed preferential binding to
296 HIV-1 PR compared to an immobilized control protein (bovine
297 serum albumin, BSA). A competitive inhibition assay was then
298 used to determine whether any of the peptides altered the
299 proteolytic activity of HIV-1 PR, in order to determine whether
300 they interacted near to the active site of the peptide, where
301 peptide sensor 2 is located (Figure 1). The FRET signal
302 between peptide sensors 1 and 2 is distance dependent, and
303 therefore peptides interacting in the vicinity of the active site
304 may result in the highest FRET eﬃciency. One of the
305 sequences (WSRVGYW) shows mild inhibitory eﬀects with a
306 Ki of 229 μM (Supporting Information, Figure S2).
307 Given the single active site of the protease, the competitive
308 inhibition shown in Figure 2b implies that WSRVGYW must
309 interact in the vicinity of the active site. It was thus identiﬁed as
310 the most promising sequence found through phage display
311 since it is expected to be positioned close to peptide sensor 2,
312 which should maximize the FRET eﬃciency. Peptide sensor 1
313 was fabricated by synthesizing WSRVGYW and conjugating a
314 ﬂuorescent molecule, Alexa Fluor 647 (AF647), to the N-
315 terminus. Peptide sensor 2 was fabricated by synthesizing the
316 inhibitory sequence LLEYSL, to a Black Hole Quencher-3
317 (BHQ-3), also through the N-terminus. Both sensors form a
318 FRET pair in which BHQ-3 acts as a dark quencher for the
319 ﬂuorescent AF647 dye. Thus, if both peptide sensors are
320 simultaneously interacting with a single protease molecule, a
321 decrease in the ﬂuorescence of AF647 should be observed.
322HIV-1 PR was immobilized on amine functionalized glass
323slides using glutaraldehyde coupling. After unreacted groups
324were blocked, the slide was incubated for an hour with peptide
325sensor 1 at a concentration of 210 μM. After thoroughly
326washing the membrane for an hour to remove nonspeciﬁcally
327 f3bound dye, the slide was imaged (Figure 3a). The interaction
328between the peptide sensors 1 and the HIV PR can be clearly
329observed in Figure 3a. When the slide was incubated with
330peptide sensor 2 at a concentration of 609 μM, the ﬂuorescent
331signal was quenched (Figure 3b). The decrease in ﬂuorescence
332was not seen when the peptide was incubated with a nonlabeled
333version of LLEYSL, which demonstrates that it is originated by
334FRET and not by competition for the biorecognition of the
335protease (see Supporting Information, Figure S3). This
336supports the hypothesis that both peptides are binding to the
337protease giving multiple independent recognition events.
338Furthermore, when the membrane was incubated in the
339working buﬀer, no signal decrease was observed, which
340demonstrates that the decrease in ﬂuorescent signal did not
341originate by washing peptide sensor 1 oﬀ the protein (Figure
3423b). No FRET was observed when the two peptide sensors
343were incubated in the absence of HIV-1 PR (Supporting
344Information, Figure S3). These experiments demonstrate that it
345is possible to detect HIV PR with the proposed detection
346scheme based in the dual biorecognition by peptide sensors.
347The peptide sensors can detect immobilized HIV-1 PR at the
348concentration of 800 nM or higher (Supporting Information,
349Figure S4). This concentration value is likely dictated by the
350Koff of the WSR peptide (Kd = 44.6 μM). The binding aﬃnity
351of the LLEYSL peptide is much stronger (Kd = 3.04 nM), and
352hence, the sensitivity of the assay will lie between these two
353values (Supporting Information, Figure S5). Peptides found
354through phage display are well-known for displaying low to
355moderate binding aﬃnity.15
356We next performed molecular dynamics (MD) simulations in
357order to ascertain whether it would be possible for both
358peptides to interact with the enzyme’s active site simulta-
359neously, giving rise to the observed FRET signal and to conﬁrm
360our design principles.
361Initial molecular docking of the inhibitor peptide LLEYSL
362and the best binding sequence from phage dis-play to the
363protease was performed using Autodock 4.223 in order to
364identify energetically favorable starting structures of the
365molecular complexes which were then simulated using classical
Figure 3. On surface FRET showing detection of HIV-1 PR using two
independent recognition events. (a) Quantiﬁcation of ﬂuorescence
quenching on surface. Error bars shown are standard deviation (n = 3).
Signiﬁcance is given by a two-tailed student t test. (b) The presence of
immobilized HIV-1 PR can be seen through the ﬂuorescence signal of
nanosensor 1 (WSR-AF647). On addition of nanosensor 2 (LLE-
BHQ-3) the ﬂuorescence signal is quenched. No such signal decrease
is observed through continued washing.
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366 all-atom molecular dynamics using Amber 12.24 Three
367 conformations of the protease were used, namely, with its
368 ﬂaps open, semiopen, and closed. For each conformation, three
369 areas were electrostatically mapped to explore interaction areas
370 for the peptides: the active site, the hinge region, and the
371 “bottom” of the enzyme (Supporting Information, Figure S6).
372 For each peptide/ﬂap/grid combination the top 100 docking
373 orientations were ranked using an estimated free energy of
374 binding, and for each combination the 3D structures of the top
375 10 best binders were examined. As a result, a total of 15
376 protein−ligand complexes were chosen for molecular dynamics
377 simulation, on the basis of the docking score, speciﬁcity of the
378 docking poses, and ligand contacts with the protease. Some
379 peptide/ﬂap/grid combinations did not yield any complexes
380 with favorable free energy of binding or were not signiﬁcantly
381 diﬀerent in peptide backbone position from other docking
382 poses, and thus were not considered for molecular dynamics.
383 Of the 15 peptide−protease complexes simulated, 12 were
384 found to have negative free energies of binding calculated by
385 the MM-PBSA approach. WSRVGYW was found to have a
386 favorable free energy of binding, and bound most strongly in
387 the active site. This is in good agreement with experimental
388 data for WSRVGYW.
389 Binding of LLEYSL in the active site is characterized by
390 hydrogen bonding of Asp30and Asp25 to the Ser side chain
391 and second Leu backbone in the peptide sequence. These
392 bonds are present in all simulations where there was a favorable
393 free energy of binding for this peptide. The strongest predicted
394 binding structures also show hydrophobic interactions between
395 the peptide Tyr and Phe53. The interaction of WSRVGYW
396 with the active site also shows signiﬁcant dependence on
397 hydrogen bonding between the N-terminus Trp backbone and
398 Ser side chain with Asp30. In these simulations, we also
399 observed several hydrophobic interactions between Tyr and the
400 C-terminus Trp with the Phe53 and Phe53 ﬂap residues,
401 similar to that seen for LLEYSL.
402 We hypothesized that binding to the hinge region of the
403 protease could have a potential inﬂuence on the activity of the
404 enzyme, since an interaction here would prevent the ﬂaps of the
405 enzyme from closing, hence preventing the formation of the
406 catalytic triad required for proteolysis. However, the
407 simulations showed that the binding of both WSRVGYW and
408 LLEYSL in this region was predicted to be orders of magnitude
409 less than in the active site. Binding conformations that originate
410in the hinge region progressively interacted with the ﬂaps over
411the course of the simulations. Because of this only a few
412hydrophobic interactions are observed between the peptides
413and the Ile residues found in the protease ﬂaps (Ile50, Ile54).
414This is to be expected given that this is the hydrophilic, solvent-
415exposed surface of the protease. From these studies it is
416therefore reasonable to suggest that both WSRVGYW and
417LLEYSL occupy the active site of HIV-1PR.
418The interactions of the peptide sensors with the protease
419were also simulated to observe the impact of the presence of
420the dye molecule on the binding. Conformational sampling was
421performed using the REST (replica exchange with solute
422tempering) procedure with convergence determined by a
423plateau in the number of new structures found by the clustering
424analysis.
425Clustering was performed on the two peptide backbones
426separately with an RMSD cutoﬀ of 1.2 Å over the ﬁnal 50 ns of
427 f4the 200 ns REST trajectory (Figure 4a). The most populated
428clusters found for both WSRVGYW and LLEYSL are
429structurally similar to their respective conformations obtained
430from the 800 ns classical molecular dynamics simulations. Both
431peptides are relatively stable in their binding positions,
432characterized by the change in free energy as a function of
433the peptide radial distance from the HIV-1 PR catalytic residues
434(Supporting Information, Figure S7). An enhanced discussion
435of the clustering is given in the Supporting Information.
436Interestingly, there are similar features between the binding
437interactions of the two peptides (Figure 4b). Both sensors form
438a hydrogen bond with the Gly48 backbone of the protease ﬂap,
439and both have persistent hydrophobic contacts with the
440hydrophobic pocket formed by Ile50, Val82, Ile84, and
441Leu23, as well as hydrophobic contacts with Phe53 on the
442protease ﬂap. The experimentally observed inhibitory action of
443both peptides may be due to interference with the opening of
444the ﬂaps rather than occupation of the active site as seen with
445other inhibitors.29
446To demonstrate the potential of this technique for one-step
447diagnostics and to test whether our designed peptide sensors
448generated a high eﬃciency signal, the FRET assay was
449performed with the enzyme free in a buﬀered solution. In
450this case the peptides were synthesized with ﬂuorescein and
451rhodamine conjugated to the N-terminus. These were
452designated LLE-ﬂuor and WSR-rhod, respectively. This was
453done to modulate the ﬂuorescence intensity of the rhodamine
Figure 4. Simulated structure of HIV-1 PR complexed with peptide nanosensors: (a) The most populated cluster from REST simulations showing
both peptide−dye conjugates bound to the protease ﬂaps on opposite sides of the active site. WSRVGYW is shown in red, and LLEYSL is shown in
green. (b) Contact maps showing the interaction probabilities with HIV-1 PR for each residue of the nanosenors for the most populated cluster of
the peptide−dye conjugates. Residue 1 represents the contacts between the dye or quencher to the protease, and the peptides are subsequently
numbered from N-terminus to C-terminus.
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454 which is highly pH dependent and more sensitive to cross-
455 excitation at lower pH.
30At this pH the protease is less active
456 but not conformationally aﬀected since its high pI means it is
457 most stable between pH 4 and 6.
31 HIV-1 PR was incubated
458 with both peptide sensors at a concentration of 20 μM (LLE-
459 ﬂuor and WSR-rhod) for 1 h in the dark at 4 °C. The assay was
460 incubated in the cold in order to slow the Koff rate of the
461 peptides and thus improve the assay’s sensitivity.
462 The FRET assay has a limit of detection of 654 nM
463 calculated as the concentration of analyte that yields a signal
464 higher than 3 times the standard deviation on the blank, 3σ
f5 465 (Figure 5). This is in good agreement with the lowest
466 concentration which is observable by eye in the immobilized
467 experiments (Supporting Information, Figure S4). In order to
468 understand the low limit of detection observed for this assay,
469 the FRET eﬃciency was calculated using time correlated single
470 photon counting spectroscopy (TCSPC) in the presence of 4
471 μM HIV-1 PR (Supporting Information, Figure S8).
472The ﬂuorescence lifetime of the donor molecule (ﬂuo-
473rescein) in the presence and absence of the acceptor
474(rhodamine) was measured. In the absence of the acceptor, a
475single exponential gives a lifetime of 3.92 ns. In the presence of
476the acceptor the data follows a single-exponential yielding a
477decay of 3.53 ns. From this, using eq 1 where τD is the donor
478ﬂuorescence in the absence of acceptor and τDA is the
479ﬂuorescence of the donor in the presence of an acceptor, we
480can calculate an eﬃciency of only 9.95%.
τ
τ
= −E 1
DA
D 481(1)
482This low eﬃciency could be explained by several factors.
483First, it is possible that WSR-rhod is interacting with the
484enzyme further from the active site than is predicted by the
485models above (the simulations suggest a center-of-mass to
486center-of-mass distance between the two dye molecules of 2.68
487(±0.27) nm). Second there is likely a dominant eﬀect of the
488high koff of WSR-rhod.
Figure 5. (a) Steady-state emission spectra of FRET in solution showing an increasing ﬂuorescence transfer with increasing concentrations of HIV-1
PR (λex = 480 nm) following a 1 h incubation at 4 °C. (b) Variation of the FRET signal with the concentration of HIV PR showing the limit of
detection calculated as 3σ.
Figure 6. Comparison of assay speciﬁcity using diﬀerent enzymes: (a) The commercial HIV-1 substrate shows some vulnerability to nonspeciﬁc
cleavage by pepsin, an aspartyl protease but not to enzymes from a diﬀerent family. (b) The assay developed here shows no response to an excess of
pepsin when compared to the blank control.
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489 Although we do not see two populations in the lifetime
490 measurements that would indicate the presence of an
491 unquenched population, the low rate of energy transfer may
492 mask this eﬀect. Since the concentration of WSR-rhod used in
493 this assay is below the KD of the peptide we can assume that at
494 this concentration only 30.9% of PR molecules are labeled with
495 an acceptor, while >99.98% of molecules will be labeled with a
496 donor molecule.
497 Calculating a distance between a FRET pair is diﬃcult with
498 such a low eﬃciency since the r6 dependence becomes
499 insensitive to changes above the Förster distance. Diﬀerences
500 between the calculated distance from the FRET studies (7.60
501 nm) and that expected from the MD may also arise due to the
502 diﬀerent structure of the dye molecules which act as a reporter
503 probe (AF647/BHQ-3 vs ﬂuorescein/rhodamine) which may
504 aﬀect the calculated binding orientation, leading to diﬀerences
505 in center-of-mass distances. Other diﬀerences may occur due to
506 variations of the orientation factor (κ is assumed to be 2/3 when
507 the dyes are free to rotate). Diﬀerences in this value would
508 impact the Förster radius used to calculate the dye−dye
509 distance. The use of rhodamine as an acceptor dye can also
510 introduce errors to this calculation due to its broad absorption
511 spectrum and hence signiﬁcant direct excitation.
512 A major advantage of the proposed detection strategy
513 compared to classical approaches based on cleavable peptide
514 substrates is the high speciﬁcity of the detection due to the
515 multiple interaction events. In a conventional assay, proteases
516 with similar speciﬁcity to the target protease can also cleave
517 peptides with FRET pairs leading to false positives. Our test
518 does not rely on substrate cleaving and requires two
519 independent biorecognition events, which increases the
520 speciﬁcity of the assay. To prove the speciﬁcity of the proposed
521 detection scheme, the assay was repeated using pepsin. Pepsin
522 is the most ubiquitous of the aspartyl proteases and
523 demonstrates a broad substrate recognition.
524 Pepsin at the manufacturer’s recommended working
525 concentration of 4 mg/mL was incubated at pH 2 (the optimal
526 pH for pepsin activity) with the commercial HIV-1 protease
527 substrate used for inhibition studies above. This acts as a model
528 system of a FRET pair linked through a cleavable peptide
529 substrate.
f6 530 Figure 6a shows that the commercial system is vulnerable to
531 nonspeciﬁc cleavage since it yields a positive signal in the
532 presence of pepsin. The enzyme papain, a cysteine protease, is
533 included as a control from a diﬀerent enzymatic family to show
534 that substrates are usually vulnerable to nonspeciﬁc enzymes
535 from structurally similar enzymes. In comparison, Figure 6b
536 shows the same concentration of pepsin (at large excess)
537 incubated with the peptide sensors. The experimental
538 conditions are identical to those used for the in-solution
539 FRET assay described above. In this instance, no diﬀerence can
540 be observed between the blank and the pepsin therefore
541 conﬁrming our hypothesis that using two peptide sensors
542 results in highly speciﬁc signals.
543 ■ CONCLUSIONS
544 We have demonstrated that HIV-1 protease, a critical enzyme
545 in the lifecycle of HIV/AIDS, can be detected through designed
546 interactions with multiple peptide sensors. This approach to
547 biomarker detection requires two independent binding events,
548 a strategy that improves the speciﬁcity of the assay. Our
549 methodology is also diﬀerentiated from other protease-based
550 assays in that the signal is not dependent on proteolytic
551cleavage which can be susceptible to nonspeciﬁc enzymes. We
552also remove the need for the multiple wash steps that are
553required with conventional ELISA assays, streamlining the
554laboratory process. While the aﬃnity of the peptide sensor
555found through phage display to HIV-1 PR is lower than would
556be expected from an antibody, we believe the advantages in
557environmental stability and length scale make these sensors
558well-suited to FRET applications. Through molecular dynamics
559simulations we have explored the interaction between the
560protease and the peptides to understand the mechanisms which
561cause these binding events and developed a model for the
562simultaneous binding of both peptide sensors to HIV-1
563protease. It is hoped that our assay will provide a new direction
564for the design of highly speciﬁc protein sensing without the
565need for costly antibody development.
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